Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Notes Payables: 2011-2025

Historic Notes Payables for Iovance Biotherapeutics (IOVA) over the last 2 years, with Sep 2025 value amounting to $1.0 million.

  • Iovance Biotherapeutics' Notes Payables was N/A to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2011, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Notes Payables is $1.0 million, which was down 0.00% from $1.0 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Notes Payables' 5-year high stood at $1.0 million during Q1 2025, with a 5-year trough of $1.0 million in Q1 2025.
  • Its 1-year average for Notes Payables is $1.0 million, with a median of $1.0 million in 2025.